AI
Commented by Nico Popp on July 11th, 2025 | 07:00 CEST
Think locally, benefit globally: JinkoSolar, Kontron, naoo
It is old news that decentralized solutions are better - those who understand how village communities were largely self-sufficient and supported each other complementarily just a few decades ago know the blueprint for economic success. Decentralized solutions have long played a key role in energy supply. The boom in private solar installations shows that resourceful property owners have recognized the potential. But other industries also benefit when complementary elements are brought together.
Read
Commented by Nico Popp on July 10th, 2025 | 07:25 CEST
Small-cap disrupts billion-dollar market: Johnson & Johnson, Merck KGaA, and NetraMark
When it comes to making people healthy, progress is what matters most. New drugs must be better and safer than old ones. To ensure that these requirements are met, comprehensive testing procedures are carried out by drug regulatory authorities. However, despite ever-expanding knowledge and modern methods, almost 90% of clinical trials still fail. When considering that the development of a drug costs an average of USD 2.6 billion and usually takes more than ten years, it becomes clear what a risk biotech companies and pharmaceutical multinationals are taking. This is precisely where NetraMark's business model comes in, offering the entire industry unparalleled leverage.
Read
Commented by Armin Schulz on July 10th, 2025 | 07:15 CEST
How BioNTech, PanGenomic Health, and Pfizer are using artificial intelligence to cut costs and boost returns
Digitalization is revolutionizing the biotechnology and pharmaceutical industries. Artificial intelligence sifts through billions of pieces of medical data in real time, accelerating drug development by years. This is also demonstrated by the new alliance between Moderna and Google Cloud, which are jointly developing an AI platform for customized mRNA cancer therapies. These technologies reduce production costs by up to 40% and generate disruptive return opportunities. At the same time, personalized medicine is opening up billion-dollar markets. Three companies are turning to artificial intelligence to boost their returns: BioNTech, PanGenomic Health, and Pfizer.
Read
Commented by Armin Schulz on July 10th, 2025 | 07:05 CEST
Deutsche Telekom, MiMedia, Xiaomi: Three stocks benefiting from the cloud and AI revolution
By 2025, cloud services and artificial intelligence (AI) will become increasingly important. AI infrastructures have become a critical competitive nerve center. Hyperscaling and agentic systems are revolutionizing value chains; those who hesitate will lose out. The drivers are platforms such as Microsoft's new AI cloud generation, which enables the real-time integration of generative AI into core processes. This hyperscaling reduces costs, enhances data protection, and accelerates AI adoption in data-intensive sectors. A billion-dollar market is emerging for pioneers. Three players have strategically positioned themselves: Deutsche Telekom, MiMedia, and Xiaomi.
Read
Commented by Armin Schulz on July 2nd, 2025 | 07:10 CEST
AI, personalized therapies, blockbusters: Evotec, NetraMark Holdings, Novo Nordisk – Your ticket to the pharmaceutical boom
As billion-dollar profits beckon and technological quantum leaps revolutionize the healthcare industry, investor excitement is surging in 2025. Investors are flocking back, attracted by unprecedented momentum. Artificial intelligence is discovering new drug candidates in record time, personalized medicine is unlocking entirely new markets, and solutions for widespread chronic diseases are driving valuations to dizzying heights. Those who understand the rules of this rapid change and identify the right partners are positioning themselves for exceptional returns. We therefore take a closer look at three compelling companies in this space: Evotec, NetraMark Holdings, and Novo Nordisk.
Read
Commented by André Will-Laudien on June 30th, 2025 | 07:35 CEST
Takeover fever! Biotech and artificial intelligence boost Evotec, NetraMark Holdings, Novo Nordisk, and Bayer
The biotech sector is currently undergoing an exciting transformation, as big data and artificial intelligence are rapidly changing the way new drugs are discovered, developed, and tested. The use of learning algorithms allows molecular target structures to be identified more quickly and potential active ingredients to be evaluated more efficiently. Start-ups and established players alike are increasingly turning to data-driven platforms to reduce research costs and increase the success rate of clinical trials. As a result, capital is increasingly flowing into companies that use modern data analysis to drive biotechnology. Approaches that enable personalized medicine - treatments precisely tailored to an individual's specific condition - are in particularly high demand. For investors, this represents a promising growth sector with enormous disruptive potential. But who are the most interesting players?
Read
Commented by Nico Popp on June 25th, 2025 | 07:15 CEST
New trends in aerospace are driving growth: Volatus Aerospace, Lockheed Martin, Boeing
The new global security situation shows that military potential can secure peace. Even if staunch pacifists proclaim the opposite, the latest measures taken by Israel and the US against Iran have demonstrated that decisive action pays off – the mullah state's nuclear program appears to have been significantly delayed, at the very least. Military innovations have been particularly significant in the aerospace sector in recent years. However, many formerly purely military approaches are also proving their worth in civilian applications. We take a look at Lockheed Martin, Boeing, and Volatus Aerospace, highlight their innovations, and venture a look at how their shares are likely to perform.
Read
Commented by Armin Schulz on June 24th, 2025 | 07:30 CEST
Portfolio Doubler with Artificial Intelligence: Novo Nordisk, PanGenomic Health, and Pfizer Ignite the Profit Growth in 2025
According to BlackRock Health Sciences, the global healthcare sector is poised for an unprecedented boom in 2025. After years of volatility driven by the pandemic, the industry is now expected to achieve its highest profit growth in almost two decades - and across the board, not just among pandemic-driven outliers. Digital revolutions such as AI-assisted drug development and telemedicine are accelerating change and creating radically new business models. Those who understand the architects of this transformation will recognize the growth drivers of tomorrow. With this in mind, we take a closer look at three key companies: Novo Nordisk, PanGenomic Health, and Pfizer.
Read
Commented by Stefan Feulner on June 24th, 2025 | 07:25 CEST
Revolution in the pharmaceutical industry – NetraMark beats ChatGPT by a mile
It was a real bombshell when NetraMark announced yesterday, shortly before the US stock market opened, that a preprint published on the arXiv portal shows that the Company's proprietary AI, NetraAI, is not only technologically ahead but also measurably outperforms leading models like ChatGPT and DeepSeek. In the analysis of clinical study data, NetraAI delivers the only statistically valid and medically actionable results. This positions the Canadian company as a potential game changer in a billion-dollar market where traditional machine-learning methods often fall short.
Read
Commented by Fabian Lorenz on June 19th, 2025 | 07:05 CEST
Share price speculation thanks to drones and artificial intelligence: Rheinmetall, BioNTech, and NetraMark shares
Drones and artificial intelligence are set to revolutionize entire industries. Listed companies that play a leading role in this transformation hold significant upside potential, such as NetraMark. Using artificial intelligence, the Company helps pharmaceutical and biotech companies shorten development times and reduce costs. NetraMark also aims to help shape industry trends. BioNTech, too, relies on AI for its research, frequently acquiring specialized companies. Perhaps NetraMark will be next? In any case, the Canadians would still be a bargain. Rheinmetall shares, on the other hand, are certainly not cheap. However, the multibillion-euro defense budgets for rearmament in Europe are fueling speculation. In order to be able to deliver not only tanks, howitzers, and ammunition quickly, but also cutting-edge technology, Germany's largest defense contractor is focusing on partnerships. This is evident in its latest partnership, which is expected to enable Rheinmetall to deliver combat and kamikaze drones quickly.
Read